化学
拓扑异构酶
抗体-药物偶联物
连接器
药理学
单克隆抗体
体外
癌症研究
药品
体内
抗体
医学
免疫学
生物化学
生物
计算机科学
操作系统
生物技术
作者
Yusuke Ogitani,Yuki Abe,Takuma Iguchi,Junko Yamaguchi,Tomoko Terauchi,Michiko Kitamura,Kōichi Goto,Motoaki Goto,Masataka Oitate,Hideo Yukinaga,Yoshiyuki Yabe,Takashi Nakada,Takeshi Masuda,Koji Morita,Toshinori Agatsuma
标识
DOI:10.1016/j.bmcl.2016.08.082
摘要
To establish a novel and widely applicable payload-linker technology for antibody–drug conjugates (ADCs), we have focused our research on applying exatecan mesylate (DX-8951f), a potent topoisomerase I inhibitor, which exhibits extensive antitumor activity as well as significant myelotoxicity, as the payload part. Through this study, we discovered a promising exatecan derivative (DX-8951 derivative, DXd), that has the characteristics of low membrane permeability and shows considerably less myelotoxicity than that shown by exatecan mesylate in an in vitro human colony forming unit-granulocyte macrophage assay. DXd was further used for drug conjugation by using commercially or clinically useful monoclonal antibodies to evaluate the potency of the ADC. The result revealed that the DXd-ADCs targeting CD30, CD33, and CD70 were effective against each of their respective target-expressing tumor cell lines. Moreover, a novel DXd-ADC targeting B7-H3, which is a new target for ADCs, also showed potent antitumor efficacy both in vitro and in vivo. In conclusion, this study showed that this novel topoisomerase I inhibitor-based ADC technology is widely applicable to a diverse number of antibodies and is expected to mitigate myelotoxicity, thereby possibly resulting in better safety profiles than that of existing ADC technologies.
科研通智能强力驱动
Strongly Powered by AbleSci AI